Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Agrana, ams, Frequentis, Marinomed, OMV (08/10/2020)

11.10.2020

Agrana: Agrana, the fruit, starch and sugar company, generated operating profit (EBIT) of Euro 55.8 mn in the first half of the 2020|21 financial year, a moderate increase of 7.9% year-on-year (H1 prior year: Euro 51.7 mn). Helping make the year-on-year growth in Group EBIT possible was the Sugar segment, which, as in the first quarter, saw a year-on-year improvement in earnings in the second quarter as a result of higher sugar prices. The Group's revenue rose slightly to Euro 1,309.3 mn (H1 prior year: Euro 1,250.0 mn). Chief Executive Officer Johann Marihart says: "Much of our positive business performance can be credited to the diversification of our business activities, which enables us to balance out fluctuating economic conditions in the various segments. Thus, in the first half of the year, the Starch segment was able to maintain the prior year's EBIT earnings despite significantly weaker starch sales in the paper sector, thanks to the very strong performance in bioethanol especially in the second quarter." Taking into account potential impacts of the coronavirus crisis, Agrana expects Group EBIT for the full 2020|21 financial year to at least match the prior-year level. Group revenue is projected to show slight to moderate growth of up to 10%.
Agrana: weekly performance: 0.97%

ams: ams, supplier of high performance sensor solutions, intends to issue Convertible Bonds and enter into a new bridge facility, cancelling out existing bridge facilities. The Bonds have an expected maturity of seven years. The net proceeds of the Bonds will be used to secure funding in relation to the envisaged ultimate full acquisition of Osram Licht AG as well as for general corporate purposes. The timing and terms of the placement of the Bonds, if any, will be determined subject to market conditions. In addition to the potential issuance of the Bonds, ams is in preparations to enter into a new up to Euro 750 mn bridge facility with a consortium of banks, cancelling out the existing bridge facilities.
AMS: weekly performance: 11.42%

Frequentis: The Swiss Federal Office for Defence procurement, armasuisse, has worked closely with Frequentis to complete important contract milestones despite the pandemic travel restrictions. Frequentis is replacing the voice communication infrastructure of the Air Defense Direction Centers and Military Airbases, supporting the needs of the Swiss Air Force. “The suspension of flights from mid-March initially prevented us from achieving our goals for the Swiss defence projects. Specification workshops and site acceptances were at risk in May and June, however, together with armasuisse we created an individual strategy for each milestone and the team was able to achieve success”, said Peter Skiczuk, Frequentis Vice President Defence. “Any delay to our projects would have been a logistical challenge for the following project phases. This positive result is a true reflection of the quality of the business relationship between Frequentis and armasuisse, built over more than two decades.”
Frequentis: weekly performance: 1.73%

Marinomed: Marinomed Biotech AG, a Vienna-based biopharmaceutical company, develops groundbreaking treatment for autoimmune gastritis together with the Medical University of Vienna. Aided by the Marinosolv® technology platform, for the first time, the focus will be on an anti-inflammatory treatment rather than treating only the deficiency symptoms. The goal of Marinomed is to solve the unsolvable using Marinosolv®."So far there is no anti-inflammatory treatment for autoimmune gastritis and together we will change that. Priv.-Doz. Stefanie Dabsch and ao. Univ.-Prof. Christoph Gasche as well as their team from the Medical University of Vienna bring extensive knowledge regarding the disease to the table, while we have the necessary galenic know-how. For patients, this would mean a milestone in their treatment”, says Marinomed-CEO Andreas Grassauer.
Marinomed Biotech: weekly performance: -1.80%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (08/10/2020)


Partners









latest 21st Austria

21st Austria weekly - Agrana, ams, Frequentis, Marinomed, OMV (08/10/2020)


11.10.2020, 4072 Zeichen



Agrana: Agrana, the fruit, starch and sugar company, generated operating profit (EBIT) of Euro 55.8 mn in the first half of the 2020|21 financial year, a moderate increase of 7.9% year-on-year (H1 prior year: Euro 51.7 mn). Helping make the year-on-year growth in Group EBIT possible was the Sugar segment, which, as in the first quarter, saw a year-on-year improvement in earnings in the second quarter as a result of higher sugar prices. The Group's revenue rose slightly to Euro 1,309.3 mn (H1 prior year: Euro 1,250.0 mn). Chief Executive Officer Johann Marihart says: "Much of our positive business performance can be credited to the diversification of our business activities, which enables us to balance out fluctuating economic conditions in the various segments. Thus, in the first half of the year, the Starch segment was able to maintain the prior year's EBIT earnings despite significantly weaker starch sales in the paper sector, thanks to the very strong performance in bioethanol especially in the second quarter." Taking into account potential impacts of the coronavirus crisis, Agrana expects Group EBIT for the full 2020|21 financial year to at least match the prior-year level. Group revenue is projected to show slight to moderate growth of up to 10%.
Agrana: weekly performance: 0.97%

ams: ams, supplier of high performance sensor solutions, intends to issue Convertible Bonds and enter into a new bridge facility, cancelling out existing bridge facilities. The Bonds have an expected maturity of seven years. The net proceeds of the Bonds will be used to secure funding in relation to the envisaged ultimate full acquisition of Osram Licht AG as well as for general corporate purposes. The timing and terms of the placement of the Bonds, if any, will be determined subject to market conditions. In addition to the potential issuance of the Bonds, ams is in preparations to enter into a new up to Euro 750 mn bridge facility with a consortium of banks, cancelling out the existing bridge facilities.
AMS: weekly performance: 11.42%

Frequentis: The Swiss Federal Office for Defence procurement, armasuisse, has worked closely with Frequentis to complete important contract milestones despite the pandemic travel restrictions. Frequentis is replacing the voice communication infrastructure of the Air Defense Direction Centers and Military Airbases, supporting the needs of the Swiss Air Force. “The suspension of flights from mid-March initially prevented us from achieving our goals for the Swiss defence projects. Specification workshops and site acceptances were at risk in May and June, however, together with armasuisse we created an individual strategy for each milestone and the team was able to achieve success”, said Peter Skiczuk, Frequentis Vice President Defence. “Any delay to our projects would have been a logistical challenge for the following project phases. This positive result is a true reflection of the quality of the business relationship between Frequentis and armasuisse, built over more than two decades.”
Frequentis: weekly performance: 1.73%

Marinomed: Marinomed Biotech AG, a Vienna-based biopharmaceutical company, develops groundbreaking treatment for autoimmune gastritis together with the Medical University of Vienna. Aided by the Marinosolv® technology platform, for the first time, the focus will be on an anti-inflammatory treatment rather than treating only the deficiency symptoms. The goal of Marinomed is to solve the unsolvable using Marinosolv®."So far there is no anti-inflammatory treatment for autoimmune gastritis and together we will change that. Priv.-Doz. Stefanie Dabsch and ao. Univ.-Prof. Christoph Gasche as well as their team from the Medical University of Vienna bring extensive knowledge regarding the disease to the table, while we have the necessary galenic know-how. For patients, this would mean a milestone in their treatment”, says Marinomed-CEO Andreas Grassauer.
Marinomed Biotech: weekly performance: -1.80%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (08/10/2020)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsenradio Live-Blick, Fr. 19.4.24: DAX eröffnet zum April-Verfall deutlich schwächer, Beiersdorf und adidas stark, Gold auch




 

Bildnachweis

Aktien auf dem Radar:Amag, Palfinger, SBO, Addiko Bank, Flughafen Wien, Austriacard Holdings AG, EVN, EuroTeleSites AG, Pierer Mobility, Semperit, Bawag, Kostad, Wolford, Oberbank AG Stamm, Polytec Group, ams-Osram, Agrana, CA Immo, Erste Group, Immofinanz, Kapsch TrafficCom, Mayr-Melnhof, OMV, Österreichische Post, Strabag, Telekom Austria, Uniqa, VIG, Wienerberger, Covestro, Sartorius.


Random Partner

VARTA AG
Die VARTA AG produziert und vermarktet ein umfassendes Batterie-Portfolio von Mikrobatterien, Haushaltsbatterien, Energiespeichersystemen bis zu kundenspezifischen Batterielösungen für eine Vielzahl von Anwendungen, und setzt als Technologieführer in wichtigen Bereichen die Industriestandards.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten